Drugs / EDELINONTRINE
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT05437094 | Jun → Aug 2022 | heart failure | Cardurion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02785770 | Jun → Oct 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02114203 | Dec 2014 → Sep 2016 | sickle cell disease | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01097876 | Apr → Jul 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00959803 | Aug → Nov 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00886093 | Apr → May 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00832052 | Jan → May 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00736528 | Aug → Sep 2008 | — | Pfizer | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05409183 | May 2022 → May 2023 | symptomatic heart failure | Cardurion Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00930059 | Sep 2009 → Sep 2010 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00988598 Comparator | Oct 2009 → Jul 2010 | Alzheimer disease | Pfizer | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EDELINONTRINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2179105 ↗ |
| Known as | CRD-740 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05409183 ↗ |
| Known as | Edelinontrina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2179105 ↗ |
| Known as | PF-04447943 | “PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease” PMID 30597771 ↗ Dec 2018 |
| Known as | PF-4447943 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2179105 ↗ |
| Action | Inhibit | “PF-04447943, a phosphodiesterase 9A inhibitor” PMID 30597771 ↗ Dec 2018 |
| Modality | Small molecule | — CHEMBL2179105 ↗ |
| Route | Oral | “multiple, ascending, oral doses” NCT00736528 ↗ |
| Target | PDE9A | “PF-04447943, a phosphodiesterase 9A inhibitor” PMID 30597771 ↗ Dec 2018 |